N4 Pharma PLC - Asset Resilience Ratio

Latest as of December 1990: 0.13%

N4 Pharma PLC (N4P) has an Asset Resilience Ratio of 0.13% as of December 1990. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See N4P working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

GBX20.00K
≈ $2.43 USD Cash + Short-term Investments

Total Assets

GBX15.85 Million
≈ $1.93K USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (1990–2016)

This chart shows how N4 Pharma PLC's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see N4 Pharma PLC assets under control.

Liquid Assets Composition Over Time

This chart breaks down N4 Pharma PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore N4P strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents GBX0.00 0%
Short-term Investments GBX20.00K 0.13%
Total Liquid Assets GBX20.00K 0.13%

Asset Resilience Insights

  • Limited Liquidity: N4 Pharma PLC maintains only 0.13% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

N4 Pharma PLC Industry Peers by Asset Resilience Ratio

Compare N4 Pharma PLC's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Kamada
TA:KMDA
Drug Manufacturers - Specialty & Generic 0.00%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Viatris Inc
NASDAQ:VTRS
Drug Manufacturers - Specialty & Generic 1.48%
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
Drug Manufacturers - Specialty & Generic 4.31%
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
Drug Manufacturers - Specialty & Generic 1.01%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Drug Manufacturers - Specialty & Generic 5.90%

Annual Asset Resilience Ratio for N4 Pharma PLC (1990–2016)

The table below shows the annual Asset Resilience Ratio data for N4 Pharma PLC.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2016-12-31 20.75% GBX232.00K
≈ $28.23
GBX1.12 Million
≈ $136.03
+20.63pp
1990-12-31 0.13% GBX20.00K
≈ $2.43
GBX15.85 Million
≈ $1.93K
--
pp = percentage points

About N4 Pharma PLC

LSE:N4P UK Drug Manufacturers - Specialty & Generic
Market Cap
$48.10K
GBX395.33 Million GBX
Market Cap Rank
#31645 Global
#1214 in UK
Share Price
GBX0.48
Change (1 day)
+0.00%
52-Week Range
GBX0.45 - GBX0.73
All Time High
GBX32.90
About

N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequen… Read more